• Citer

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

par Almhanna, Khaldoun;Bendell, Johanna;Firdaus, Irfan;Messersmith, Wells;Ye, Zhan;Fasanmade, Adedigbo A.A.;Danaee, Hadi;Kalebic, Thea;Miron, Maria Luisa Limon;Wright, David;Gracian, Antonio Cubillo;Hubner, Richard R.A.;Van Laethem, Jean-Luc ;López, Carolina Muriel;Alsina, Maria;Muñoz, Frederico Longo
Référence Investigational new drugs, 35, 2, page (235-241)
Publication Publié, 2017-04

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
Auteur:	Almhanna, Khaldoun; Bendell, Johanna; Firdaus, Irfan; Messersmith, Wells; Ye, Zhan; Fasanmade, Adedigbo A.A.; Danaee, Hadi; Kalebic, Thea; Miron, Maria Luisa Limon; Wright, David; Gracian, Antonio Cubillo; Hubner, Richard R.A.; Van Laethem, Jean-Luc; López, Carolina Muriel; Alsina, Maria; Muñoz, Frederico Longo
Informations sur la publication:	Investigational new drugs, 35, 2, page (235-241)
Statut de publication:	Publié, 2017-04
Sujet CREF:	Cancérologie
	Pharmacologie
Mots-clés:	Antibody–drug conjugate
	Gastrointestinal cancer
	Guanylyl cyclase C
	TAK-264
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6997
	info:doi/10.1007/s10637-017-0439-y
	info:scp/85012198774